291 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
Pharmaceuticals' (Nasdaq: JAZZ) RYLAZE, Merck and Co.’s (NYSE: MRK) VAXNEUVANCE and Travere Therapeutics’ (Nasdaq: TVTX) FILSPARI, partially offset
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
valuation allowance during the fourth quarter of 2022, which was partially offset by a non-cash gain of $44.2 million from the value of Ligand's short-
term … , partially offset by an increase in R&D expenses due to the Novan acquisition. General and administrative expenses were $52.8 million for 2023
8-K
EX-10.1
2jt zb08e
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
llzk6fndzm ty29coi3
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-10.1
n8sxztov4phukb19u
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
8-K
EX-99.1
iv6gf5h0
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
425
f1g6v4om49jzzb0v
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
17rr3up jtspnjgc2
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
jzpr883exfuxtr rbz4t
24 Mar 22
Entry into a Material Definitive Agreement
9:08am